659 filings
Page 20 of 33
POS AM
2apch0es
3 Dec 10
Prospectus update (post-effective amendment)
12:00am
8-K
mm6bswj
8 Nov 10
OncoGenex Pharmaceuticals Names Michelle Burris Executive Vice President, Operations and Chief Financial Officer
12:00am
8-K
779vvaxv ob1nzeez7
4 Nov 10
Results of Operations and Financial Condition
12:00am
8-K
vci tp1m1
22 Oct 10
OncoGenex Pharmaceuticals, Inc. Closes $50 Million Public Offering
12:00am
424B5
hjoe8tqgo8501dlo
19 Oct 10
Prospectus supplement for primary offering
12:00am
8-K
gh2oeap
19 Oct 10
OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering
12:00am
424B3
oafe9w rdr
18 Oct 10
Prospectus supplement
12:00am
8-K
4s5raxw9l3 fr54dxjxk
18 Oct 10
OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering
12:00am
8-K
cnp5hfi 7tjwfb
15 Oct 10
Other Events
12:00am
8-K
4dpgapvd
30 Sep 10
Teva and Oncogenex Announce Initiation of Second Phase 3 Trial of Custirsen In Men with Metastatic Prostate Cancer
12:00am
8-K
y51ezfp6c
27 Sep 10
OncoGenex Pharmaceuticals Announces Initiation of a Phase 2 Trial Evaluating OGX-427 Treatment in Men with Advanced Prostate Cancer
12:00am
S-8
3a7ws 9e0
13 Aug 10
Registration of securities for employees
12:00am
8-K
2m8rr84x 6p4nw2gm
10 Aug 10
OncoGenex Adds David V. Smith to the Board of Directors
12:00am
8-K/A
0q83v0yq a1grftt
5 Aug 10
Submission of Matters to a Vote of Security Holders
12:00am
8-K
yfiy57k1202lxa49ndj4
5 Aug 10
Results of Operations and Financial Condition
12:00am
8-K
f3xwht1nmrrmf62
23 Jun 10
OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
12:00am
8-K
rxke j00jis3
14 Jun 10
Departure of Directors or Certain Officers
12:00am
8-K
l5stcit1v8rpn1wlp2w
7 Jun 10
OncoGenex Pharmaceuticals Announces Final Results from Phase 1 Trial Evaluating OGX-427 as a Treatment for Solid Tumors
12:00am